NCT06364852View on ClinicalTrials.gov

An Evaluation of LY007 Cell Injection for r/r B-NHL

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 25, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

May 31, 2026

Conditions
B-NHL
Interventions
DRUG

LY007

FC and LY007 infusion

Trial Locations (1)

Unknown

RECRUITING

Ruijin hospital, Shanghai

All Listed Sponsors
collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

Shanghai Longyao Biotechnology Inc., Ltd.

OTHER

lead

Ruijin Hospital

OTHER